
|Articles|December 16, 2016
ImmunoCellular Therapeutics Names New CEO
December 16, 2016
Advertisement
ImmunoCellular Therapeutics (Los Angeles, CA) announced that its Board of Directors has appointed Anthony Gringeri, Ph.D, as Chief Executive Officer. The appointment follows the decision by Andrew Gengos to resign the position of CEO. Mr. Gengos will continue to play an active role with the company as a member of the Board of Directors, the company reports. Dr. Gringeri has served as ImmunoCellular's Senior Vice President of Strategic Resources since August 2013. He joined ImmunoCellular from ViaCyte, where he was Vice President and Chief Development Officer. He previously served as Chief Operating Officer for Amsterdam Molecular Therapeutics.
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Moving From Symptom Management to Disease Modification in Parkinson’s Research: Q&A with Dr. Jan Stoehr
2
FDA Approves Otsuka’s First-In-Class Simtriyo for Adults & Pediatric Patients
3
Pharmaceutical Executive Daily: FDA Approves Simtriyo
4
Why Gross-to-Net Internal Controls Should Be a Launch Priority for Specialty Pharma Companies
5




